PMV Pharmaceuticals (PMVP) Operating Expenses (2019 - 2026)
PMV Pharmaceuticals' (PMVP) quarterly Operating Expenses came in at $19.0 million in Q1 2026, down 11.8% YoY from $21.6 million in Q1 2025, and down 1.16% on a QoQ basis from $19.2 million in Q4 2025.
PMV Pharmaceuticals (PMVP) Operating Expenses (2019 - 2026) Analysis & Trends
PMV Pharmaceuticals (PMVP) has 8 years of Operating Expenses data on file, last reported at $19.0 million in Q1 2026.
- Quarterly Operating Expenses fell 11.8% year-over-year to $19.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $83.7 million (down 5.78% YoY) and the FY2025 annual result came in at $86.2 million, up 0.89% from the prior year.
- Operating Expenses declined to $19.0 million in Q1 2026, from $19.2 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $25.2 million in Q4 2024 to a low of $17.9 million in Q2 2022.
- A 5-year average of $20.5 million and a median of $20.1 million in 2023 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses jumped 59.49% — and 2025, when it dropped 23.55%.
- Tracing PMVP's Operating Expenses over 5 years: stood at $21.2 million in 2022, then retreated by 10.68% to $18.9 million in 2023, then surged by 33.15% to $25.2 million in 2024, then retreated by 23.55% to $19.2 million in 2025, then slipped by 1.16% to $19.0 million in 2026.
- The last three Operating Expenses figures came in at $19.0 million (Q1 2026), $19.2 million (Q4 2025), and $22.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.54 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 59.41 Bn | 54.27 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - | 541.02 Mn |
| 10 | PMV Pharmaceuticals | 69.94 Mn | -9.49 Mn | - | 18.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.02 Mn |
| Dec 31, 2025 | 19.24 Mn |
| Sep 30, 2025 | 22.52 Mn |
| Jun 30, 2025 | 22.88 Mn |
| Mar 31, 2025 | 21.56 Mn |
| Dec 31, 2024 | 25.17 Mn |
| Sep 30, 2024 | 21.89 Mn |
| Jun 30, 2024 | 20.17 Mn |
| Mar 31, 2024 | 18.22 Mn |
| Dec 31, 2023 | 18.90 Mn |
| Sep 30, 2023 | 19.63 Mn |
| Jun 30, 2023 | 20.12 Mn |
| Mar 31, 2023 | 21.48 Mn |
| Dec 31, 2022 | 21.16 Mn |
| Sep 30, 2022 | 19.38 Mn |
| Jun 30, 2022 | 17.89 Mn |
| Mar 31, 2022 | 18.62 Mn |
| Dec 31, 2021 | 18.47 Mn |
| Sep 30, 2021 | 15.10 Mn |
| Jun 30, 2021 | 13.05 Mn |